BMS And Allergan Link For Pain Drug | March 8, 2010 Issue - Vol. 88 Issue 10 | Chemical & Engineering News
Volume 88 Issue 10 | p. 19 | Concentrates
Issue Date: March 8, 2010

BMS And Allergan Link For Pain Drug

Department: Business
Keywords: pain, eye care, drug development

Bristol-Myers Squibb and Allergan have formed an agreement to develop and commercialize Allergan’s AGN-209323, an oral drug in clinical development for neuropathic pain. Under the deal, Allergan grants BMS worldwide rights to the “Phase II ready” compound, except for use in products formulated for local delivery to the eye. BMS will pay Allergan $40 million up front and could owe the firm up to $373 million in milestone payments.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment